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Background: Model‐based meta‐analysis (MBMA) is increasingly used to
inform drug‐development decisions by synthesising results from multiple
studies to estimate treatment, dose‐response, and time‐course characteristics.
Network meta‐analysis (NMA) is used in Health Technology Appraisals for
simultaneously comparing effects of multiple treatments, to inform reimburse-
ment decisions. Recently, a framework for dose‐response model‐based network
meta‐analysis (MBNMA) has been proposed that combines, often nonlinear,
MBMA modelling with the statistically robust properties of NMA. Here, we
aim to extend this framework to time‐course models.
Methods: We propose a Bayesian time‐course MBNMA modelling framework
for continuous summary outcomes that allows for nonlinear modelling of mul-
tiparameter time‐course functions, accounts for residual correlation between
observations, preserves randomisation by modelling relative effects, and allows
for testing of inconsistency between direct and indirect evidence on the time‐
course parameters. We demonstrate our modelling framework using an illus-
trative dataset of 23 trials investigating treatments for pain in osteoarthritis.
Results: Of the time‐course functions that we explored, the Emax model gave
the best fit to the data and has biological plausibility. Some simplifying
assumptions were needed to identify the ET50, due to few observations at early
follow‐up times. Treatment estimates were robust to the inclusion of correla-
tions in the likelihood.
Conclusions: Time‐course MBNMA provides a statistically robust framework
for synthesising evidence on multiple treatments at multiple time points. The
use of placebo‐controlled studies in drug‐development means there is limited
potential for inconsistency. The methods can inform drug‐development deci-
sions and provide the rigour needed in the reimbursement decision‐making
process.
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1 | INTRODUCTION
In drug development, a key decision is whether to proceed
to a further clinical trial and if so, which follow‐up out-
comes to measure and which comparator agent(s)
to include. To inform this decision, it is important to under-
stand the onset and duration of action of not just the agent
under development, but also competitor agents. In addi-
tion, understanding the time‐course of pharmaceutical
agents is useful for licencing agencies when making deci-
sions on safety and efficacy of a new agent, and for reim-
bursement agencies making policy decisions based on
manufacturer submissions where different studies and
agents have reported results at different follow‐up times.
Model‐based meta‐analysis (MBMA) is a technique for
synthesising results of multiple studies, usually
randomised controlled trials (RCTs), to gain understand-
ing of the pharmacodynamic profile of different agents
during drug development.1 Key characteristics within this
profile are the dose‐response and time‐course relationships
of an agent, and how they compare with competitors.
MBMA has been used to understand these relationships
across studies.2-4 Some MBMAs have used indirect evi-
dence to compare several agents simultaneously.5-7 How-
ever, these types of analyses typically model each agent
separately, based on pooling individual study arms. Whilst
this approach allows the inclusion of nonrandomised
and/or single‐arm studies and has been proposed in the
meta‐analysis literature,8 it breaks the randomisation
within RCTs and ignores within‐study comparisons, effec-
tively losing the advantages of the RCT design and poten-
tially inducing bias in the resulting estimates.9
Network meta‐analysis (NMA) allows evidence on
multiple treatments to be combined provided they form
a connected network of treatment comparisons (where
treatment refers to a distinct formulation, such as agent
and dose combination).10-14 NMA pools evidence from
RCTs in a way that respects the randomisation in the
design of the included studies. It strengthens inference
by combining all evidence (both direct and indirect) on
the comparisons of interest, under the assumption of
consistency—agreement between direct and indirect
evidence on the same treatment comparison. When
conducting an NMA, it is essential to test for inconsis-
tency where possible and consider results accordingly,
as the validity of the resulting estimates rests upon the
consistency assumption. Methods have been developed
that formally test for inconsistency in NMA,15,16 some-
thing which has not previously been possible when
making indirect comparisons in MBMA.
However, recently, MBMA has been extended to incor-
porate a formal consistency framework by combining
ideas from NMA and MBMA in the context of dose‐
response models with multiple agents.17 This model‐based
network meta‐analysis (MBNMA) approach respects the
randomisation in the included RCTs and allows for formal
testing of inconsistency in the network of evidence.
Mawdsley et al17 described their method for dose‐
response models with an outcome at a single time‐point.
In phase II and III trials, there are often multiple
follow‐up times reported within a study, which represent
repeated measures on the same individuals and so will be
correlated. This correlation needs to be accounted for
either by modelling the time‐course,18-20 or with a multi-
variate likelihood,21-24 or both.2,25 Typically for meta‐
analysis, only aggregated data are available in published
RCTs. This can lead to additional complexities when
accounting for correlations between repeated measure-
ments, as the correlation structure may not be known.
Whilst repeated observations over time may be consid-
ered discrete observations, from the perspective of drug
development, where the focus is on predicting relative
efficacy at different time points, it is desirable to estimate
a continuous function that describes the relationship
between relative effects over time. In this paper, we
describe the MBNMA approach with time‐course models
for repeated observations within the included studies. We
also present methods to assess whether the included
evidence exhibits inconsistency. Note that in this paper
we focus on the time‐course relationship only, and so
the estimates are obtained for each distinct treatment
regimen (agent and dose combination).
The paper is organised as follows. We begin by describ-
ing the MBNMA framework to incorporate multiple
follow‐up times for continuous summary outcomes using
models for time‐course. We present a general framework,
indicating some of the common functional relationships
typically seen in practice and accounting for residual
correlation between time points. We also outline an
approach for model selection and critique and present
methods to assess consistency in the time‐course setting.
We illustrate the methods with an example dataset of
treatments for pain in osteoarthritis. Finally, we end with
a discussion of the methods in the context of earlier work
and indicate areas for further developments.
2 | METHODS
2.1 | Likelihood for continuous summary
outcomes
Although individual patient data (IPD) may be available
from a manufacturer's own study, it is likely that only
aggregate level data from publications are available from
other studies. We therefore develop our model at the level
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of study summaries (eg,mean differences).We assume that
for each study we have a continuous summary outcome,
such as mean outcome or log‐odds of response, yi,k,m,
together with standard errors, sei,k,m, reported for each
study i, arm k = 1, … ,Ki, and at time point m = 1, … ,Mi,
where study i has Ki arms and reports at Mi time points
and si,m gives the actual time corresponding to them
th time
point in study i. This formulation allows for different stud-
ies to report at different times. Typically,m=1 represents a
baseline observation at time si,1= 0. The treatment given in
study i, arm k, is indicated by ti,k.
Because we have repeated measures from the same
individuals within each study, the observations may be
correlated, which can be captured with a multivariate
normal likelihood:
yi;k eMVN θi;k;Σi;k  (1)
where yi,k is a vector of the observed summary measures
over time points, θi,k is a vector of modelled outcomes,
and Σi,k is an Mi × Mi covariance matrix:
where ρi;k;m1;m2 is the within‐study correlation between
summary measures at time points m1 and m2 for study i
arm k. In practice, correlations are rarely reported in
the literature and will only be available from studies
where we have IPD. In addition, the correlations esti-
mated from any available IPD will be at the individual
level, which may be different to correlations at the sum-
mary level.26
One approach to deal with unknown within‐study
correlations at the summary level, if IPD are available
or information on this correlation can be obtained from
external data, is to assume that the correlations seen
between time points for individual patients are the same
as those seen for summary measures, and also that cor-
relations in the study for which correlation information
is available also apply in the aggregate data trials.27,28
However, this might lead to ecological bias as there
is no guarantee that correlations at the individual level
will be the same as at the aggregate level. An alternative
is to estimate within‐study correlations based on the
aggregate data summaries by giving prior distributions
to the ρi;k;m1;m2 . This approach allows the possibility of
using informative prior distributions based on informa-
tion gained from external data. In order to identify cor-
relation parameters, some constraints will be required,
such as assuming a particular covariance structure. For
example, a compound symmetry structure can be
assumed, in which a single parameter, ρ, is estimated
for the correlation between all time points (assumed to
be the same across all studies): ρi;k;m1;m2 ¼ ρ. Alterna-
tively, it might be more reasonable to assume an
autoregressive AR(1) structure in which covariances
are dependent on the amount of time between observa-
tions where ρi;k;m1;m2 ¼ ρ
si;m2
−si;m1
si;2−si;1 .
When studies that report mean change from baseline
and final values at each time point are included,
they can contribute information to ρi;k;m1;m2 by modelling
separate likelihoods for both pieces of data (see below).29
2.1.1 | Mean change from baseline by time
Where aggregated summaries are reported as mean
change from baseline (baseline corresponding to
m = 1), we have summaries for time points m = 2, … ,
Mi defined as y
change
i;k;m ¼ yi;k;m − yi;k;1
 
and their standard
errors se
change
i;k;m . Covariances between mean changes from
baseline across time‐points m1 and m2 (dropping the i,k
subscripts for ease of exposition) are
Cov ym1 − y1
 
; ym2 − y1
  
¼
ρm1;m2sem1sem2 − ρ1;m1se1sem1 −
ρ1;m2se1sem2 þ se
2
1
which gives the (m1,m2)
th element of the covariance
matrix for the mean change from baselines, Σ
change
i;k .
We can then give a multivariate normal likelihood to
the aggregate mean outcomes for all time points:
y
change
i;k eMVN θchangei;k ;Σchangei;k 
where
Σi;k ¼
se2i;k;1 ρi;k;1;2sei;k;1sei;k;2 … ρi;k;1;Misei;k;1sei;k;Mi
ρi;k;1;2sei;k;1sei;k;2 se
2
i;k;2 … ρi;k;2;Misei;k;2sei;k;Mi
⋮ ⋮ ⋱ ⋮
ρi;k;1;Misei;k;1sei;k;Mi … … se
2
i;k;Mi
0BBBB@
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θ
change
i;k ¼
θi;k;2 − θi;k;1
θi;k;3 − θi;k;1
⋮
θi;k;Mi − θi;k;1
0BBB@
1CCCA:
By writing the model for mean change from baseline in
terms of the model for mean outcomes, we can combine
studies where some report mean outcomes and some
report mean change from baseline by giving each type
of data the appropriate likelihood and using a shared‐
parameter model.30 If some studies report both mean out-
comes and mean change from baseline, then both pieces
of data can be included. Modelling both outcomes simul-
taneously provides sufficient evidence to estimate the
correlations, ρi;k;m1;m2 .
29
2.2 | Time‐course model
We put the time‐course model on the aggregate‐level
means:
θi;k;m ¼ f si;m; λi;k
 
where f defines a functional relationship over time s, and
λi,k = (λ0,i,λ1,i,k,λ2,i,k,…) are a set of parameters that
describe the relationship in mean outcomes over time.
In all time‐course models, there will be a “nuisance
parameter” λ0,i which represents the “intercept” at time,
common across arms. Note that for many time‐course
models the λ0,i parameters will cancel out when using
change from baseline data. We put our modelling
assumptions on the remaining parameters, λ1,i,k,λ2,i,k,…,
leaving the λ0,i unconstrained (achieved in a Bayesian
analysis by giving independent vague prior distributions
to the λ0,i parameters).
2.2.1 | Exponential model
One of the most commonly used models is the exponen-
tial model, which has intercept λ0,i, and a single parame-
ter of interest, λ1,i,k, which represents the rate at which
the mean outcome falls over time, assuming a constant
rate of growth/decay:
θi;k;m ¼ λ0;i exp λ1;i;ksi;k;m
 
: (2)
2.2.2 | Linear model
Another model with a single parameter of interest is the
linear model:
θi;k;m ¼ λ0;i þ λ1;i;ksi;k;m (3)
where λ0,i is the intercept and λ1,i,k the fall in mean out-
come for a unit increase in time.
2.2.3 | Emax model
A functional form commonly used in pharmacometrics,
which has two parameters of interest, is the Emax model:
θi;k;m ¼ λ0;i þ
λ1;i;k × si;m
λ2;i;k þ si;m
(4)
where the intercept λ0,i, often referred to as E0, is the ini-
tial outcome at baseline (time = 0), λ1,i,k, typically
referred to as Emax, is the maximum possible effect of a
treatment relative to baseline, and λ2,i,k, typically referred
to as ET50, is the time point at which 50% of the maxi-
mum treatment effect has been achieved.
2.2.4 | Piecewise linear model
Piecewise models can allow for considerable flexibility,
though they may not so accurately resemble true biologi-
cal relationships and may not be appropriate when the
intention is to predict values close to where the pieces
meet (the “knots”). The simplest example of this is a
two‐piece linear model with a single knot at s = S:
θi;k;m ¼
λ0;i þ λ1;i;ksi;m 0 ≤ s ≤ S
λ0;i þ λ1;i;kS
 
þ λ2;i;k si;m − S
 
s > S
(
(5)
where λ0,i is the intercept, λ1,i,k the change in mean out-
come for a unit change in time during time period (0,S),
and λ2,i,k the change in mean outcome for a unit change
in time during time period after S. The intercept for the
second piece (λ0,i+λ1,i,kS) ensures that the two regression
lines meet at the knot.
2.3 | Network meta‐analysis model
The NMA model describes the impact of treatments on
one or more of the parameters of the time‐course model,
λ1,i,k,λ2,i,k,…. If the NMA model is given for a single time‐
model parameter, λ1,i,k, we have
g λ1;i;k
 
¼ μi þ δi;k
for a given link function g which transforms the outcome
to a scale where relative treatment effects may be
expected to be additive. μi is the time‐course model
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parameter (on the transformed scale) for arm 1 of study i,
and δi,k the study‐specific relative effect for the treatment
used in arm k relative to arm 1 of study i.
For example, for an exponential time‐course model
(Equation 2), it would be natural to put the NMA model
on the log‐scale:
log λ1;i;k
 
¼ μi þ δi;k
where μi is the log growth/decay rate on arm 1, and δi,k is
the log rate‐ratio for treatment arm k compared with
treatment arm 1, of study i.
The μi are nuisance parameters and given indepen-
dent vague prior distributions in a Bayesian analysis to
allow these to be unconstrained. By treating these as
nuisance parameters, the focus of this modelling strat-
egy is on estimating relative treatment effects rather
than on characterising the time‐course on the reference
treatment (eg, placebo effect). In fact, because different
studies may have included different control (arm 1)
treatments, the μi do not have a consistent interpreta-
tion across studies.
Treatment effects can be either assumed common
(“fixed”) or similar/exchangeable (“random”) across stud-
ies. For the random effects model, study‐specific treat-
ment effects are assumed to be normally distributed
around a mean treatment effect that adheres to the
consistency relationships, with common between‐studies
variance τ2 across treatment comparison:
δi;k eN d1;ti;k − d1;ti;1 ; τ2 : (6)
The consistency relationships reflect the comparison
made between the treatment ti,k used on arm k and the
treatment ti,1 used on arm 1 of each study. The fixed effect
model is obtained by setting τ2 = 0. The model estimates
“basic parameters” d1,k, the pooled mean relative effect
for treatment k relative to treatment 1 (the reference
treatment for the NMA). The d1,k are each given indepen-
dent vague normal priors in a Bayesian analysis. All other
relative effects for treatment k relative to treatment c, dc,k,
can then be derived from the consistency relation-
ships12,30:
dc;k ¼ d1;k − d1;c: (7)
Time‐course functions with multiple (nonintercept) time‐
course parameters may have NMA models specified for
one or more of these parameters, although a relatively
rich dataset is required to estimate NMA models with
more than one treatment effect parameter.
Suppose we expect the treatments to influence two
parameters of the time‐course model, λ1,i,k and λ2,i,k (for
example these could represent Emax and ET50). The
NMA model proceeds as for a single parameter; however,
for a random effects model, we need to allow for correla-
tions between the study‐specific treatment effects on the
two time‐course parameters. Note that the link functions
g do not have to be the same for the different parameters:
g1 λ1;i;k
 
¼ μ1;i þ δ1;i;k
g2 λ2;i;k
 
¼ μ2;i þ δ2;i;k
etc:
(8)
The random effects model for δ1,i,k, δ2,i,k, etc needs to be
multivariate to allow for correlations between relative
effects on the different time‐course parameters.
For example, for the Emax model, the Emax parameter
λ1,i,k can be positive or negative, and so we can put the
model on the natural scale, whereas the ET50 parameter
λ2,i,k may only take positive values, and so it makes sense
to model this on the log scale, giving
λ1;i;k ¼ μ1;i þ δ1;i;k
log λ2;i;k
 
¼ μ2;i þ δ2;i;k
with a bivariate random effects distribution:
δ1;i;k
δ2;i;k
  eN d1;1;ti;k − d1;1;ti;1d2;1;ti;k − d2;1;ti;1
 !
;
τ21 ρδτ1τ2
ρδτ1τ2 τ
2
2
 ! !
(9)
where all parameters are as before, with an extra subscript
to indicate whether they relate to λ1,i,k or λ2,i,k. The corre-
lation between the treatment effects on the two parame-
ters is given by ρδ. Different parameterisations are
available for the between‐studies covariance matrix that
may be more computationally stable, such as a Cholesky
parameterization or a spherical parameterization.31 Fixed
effect models can be obtained by setting the between‐study
variance parameters to 0.
2.4 | Multi‐arm trials
When including multi‐arm trials, it is important to
account for correlation between relative effects within a
trial, as all relative effects will have the same comparator.
For a common between‐study variance, the correlation
between these relative effects will be 0.5.11 For MBNMAs
with a single nonintercept time‐course parameter, this
can be done either using a multivariate normal distribu-
tion to model a vector of random effects,30 or, for the pur-
poses of writing more generic code, using a conditional
univariate distributions formulation for the random effect
of arm k > 2, given all arms from 2 to k − 132:
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When modelling multiple nonintercept time‐course
parameters, the correlation between relative effects can
be modelled simultaneously to the correlation between
the parameters ρδ using a multivariate normal distribu-
tion on a vector of random effects, δi, whose length is
equal to the number of parameters multiplied by the
number of arms, Ki, in study i. For models with two
parameters of interest, this is
δi ¼
δ1;i;k
⋮
δ1;i;K
δ2;i;k
⋮
δ2;i;K
0BBBBBBBBB@
1CCCCCCCCCA
eN
d1;1;ti;k − d1;1;ti;1
⋮
d1;1;ti;K − d1;1;ti;1
d2;1;ti;k − d2;1;ti;1
⋮
d2;1;ti;K − d2;1;ti;1
0BBBBBBBBB@
1CCCCCCCCCA
;Ωi
0BBBBBBBBB@
1CCCCCCCCCA
:
The covariance matrix, Ωi, is a 2Ki × 2Ki matrix:
Ωi ¼
τ21
τ21
2
⋯ 2ρδτ1τ2 ρδτ1τ2
τ21
2
τ21 ⋯ ρδτ1τ2 2ρδτ1τ2
⋮ ⋮ ⋱ ⋮ ⋯
2ρδτ1τ2 ρδτ1τ2 ⋯ τ
2
2
τ22
2
ρδτ1τ2 2ρδτ1τ2 ⋯
τ22
2
τ22
0BBBBBBBBBBBBB@
1CCCCCCCCCCCCCA
:
2.5 | Simplifying modelling assumptions
For models with many parameters, there may be insuffi-
cient data to be able to estimate all parameters (ie, the
parameters may not be identifiable). To aid identifiability
when there are two or more non‐nuisance parameters,
simplifying assumptions can be made to constrain the
parameters. In this way, a model can be constrained to
be as complex or simple as the data allow, provided there
is biological plausibility for any simplification. Note that
any shared parameters will be more influenced by
studies/treatments with more information (ie, those with
more observations within studies). One or more of the
following may be considered:
2.5.1 | Fixed effect models
One or more of the modelled parameters could be
modelled as a fixed treatment effect, reflecting an
assumption of homogeneity where different studies of
the same comparison estimate a common effect. So, if
there is a fixed effect model on the second parameter,
Equation 9 becomes
δ1;i;k eN d1;1;ti;k − d1;1;ti;1 ; τ21 
δ2;i;k ¼ d2;1;ti;k − d2;1;ti;1
and if there is a fixed effect model on both parameters,
Equation 9 becomes
δ1;i;k ¼ d1;1;ti;k − d1;1;ti;1
δ2;i;k ¼ d2;1;ti;k − d2;1;ti;1 :
2.5.2 | Class‐effect models
Relative treatment effects for one (or more) of the param-
eters could be assumed to come from a hierarchical
model with a common mean, which may depend on
class13,33-35:
d2;1;k e D2;class; τ2class  for k ∈ classf g: (10)
For example, in the Emax model, it may be that it is rea-
sonable to assume that treatments within the same class
might have a similar onset of action (and so have similar,
exchangeable treatment effects on ET50) but reach differ-
ent maximum effects (Emax).
An even more constrained model fixes the treatment
effects within a class to be equal:
d2;1;k ¼ D2;class for k ∈ classf g: (11)
2.5.3 | Constrain the baseline effect
To further aid identifiability of treatment effects, it may
be necessary to impose further constrains on the baseline
for one (or more) of the time‐course parameters, for
example with an exchangeable model:
δi;k
 δi;2⋮
δi; k−1ð Þ
0B@
1CAeN d1;ti;k − d1;ti;1 þ 1k − 1 ∑k − 1j¼1 δi; j − d1;ti; j − d1;ti;1 	 
; k2 k − 1ð Þσ2
 !
:
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μ2;i eN η2; σ2μ2 : (12)
This would imply that the reference treatment effects for
each study were assumed to be distributed about a single
common mean effect, η2, and would therefore only be
suitable in networks for which all included trials have
the same reference treatment (eg, placebo).
2.5.4 | Reduce to a single treatment effect
For models with multiple (nonintercept) time‐course
parameters, a further simplification is to only model
treatment effects on one of the time‐course parameters.
The other parameters are assumed to be treatment inde-
pendent and modelled on an absolute, rather than rela-
tive, scale:
g2 λ2;i;k
 
¼ μ2;i;k:
The μ2,i,k could be left unconstrained or assumed
exchangeable for each treatment within a class.
2.6 | Testing for inconsistency
To test whether the consistency assumption (Equation 7)
holds, several approaches have been proposed for identi-
fying inconsistency between direct and indirect evidence
that arises within a closed “loop” of treatments for
which independent sources of information are avail-
able.15,36 It is important to note that available loops of
treatments to test for inconsistency will depend on the
choice of reference treatment used in the network.36,37
In addition, the evidence provided by studies with three
or more arms is not independent (due to the common
reference arm), and within‐study relative effects must
be internally consistent. Therefore, loops of evidence
consisting only of studies with three or more arms will
always be consistent.
Furthermore, the choice of reference treatment for a
study with three or more arms can affect whether it is
possible to test for inconsistency. For example, suppose
we have three different studies providing evidence on P
(Placebo) vs N (Naproxen 1000 mg/d), P vs C (Celebrex
200 mg/d), and PvsNvsC, respectively. If we take P as
the reference for the three‐arm trial, then the three‐arm
trial provides estimates of PvsN and PvsC, so the model
only estimates PvsN and PvsC directly (see Figure S3A ‐
Supporting Information). The NvsC effect is derived from
the PvsN and PvsC estimates. If, on the other hand, we
take N as the reference for the three‐arm trial, then the
three‐arm trial provides estimates of PvsN and NvsC,
which together with the two‐arm evidence provides inde-
pendent estimates of PvsN, PvsC, and NvsC, and we can
test for inconsistency. We use the convention that we
take placebo as reference for all studies that include a pla-
cebo arm. In studies without placebo, we use the first
drug alphabetically, at its lowest dose.
An unrelated mean effects (UME) model does not
include constraints forced by the consistency equations
and is equivalent to fitting separate pairwise meta‐
analyses to each direct comparison whilst sharing
treatment‐independent parameters across all the compari-
sons,16 such as between‐study heterogeneity or treatment‐
independent time‐course parameters. The results from
this model can then be compared with those from the
MBNMA. A better model fit (lower deviance) or lower
standard deviations (SD) for exchangeable parameters or
random treatment effects would suggest that inconsis-
tency may be present in the network.
A more explicit method for testing inconsistency for
specific comparisons is the node‐splitting method.15 This
technique involves splitting the evidence for a given com-
parison within a loop of treatments into “direct” evidence
from head‐to‐head RCT comparisons and “indirect” evi-
dence that arises from the consistency relationships. A
Bayesian P‐value can be calculated for the treatment
effects estimated using the direct and indirect evidence,
which represents the proportion of the two posterior dis-
tributions that overlap.
Note that when performing pairwise meta‐analyses to
estimate direct evidence, the sharing of parameters across
direct comparisons for which limited information is avail-
able can make tests for inconsistency conservative, and
this should be borne in mind when interpreting them.
For models with multiple time‐course parameters
(Equation 8), it is important to consider that inconsis-
tency may be present for treatment effects on either or
both of the time‐course parameters.
Donegan et al38 present inconsistency models to
explore consistency on two parameters. We suggest test-
ing for inconsistency on each time‐course parameter
separately, because if inconsistency is identified in
either parameter for a given comparison, then this
should be a cause for concern and should prompt fur-
ther investigation of the included studies to identify
the potential cause.
Multiple testing may also be an issue here, as the num-
ber of tests in a typical network will be multiplied by the
number of time‐course parameters in the MBNMA
model. However, inconsistency tests are typically under-
powered, and we advise erring on the side of caution as
it is better to incorrectly identify inconsistency when
there is none present than to incorrectly fail to identify
inconsistency when true inconsistency is present.
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2.7 | Treatment ranking for time‐course
relationships
In NMA, it is common to calculate ranking probabilities
(probability of being first best, second best, etc) for each
treatment within a network, as this is an easily interpret-
able measure for decision‐makers to use. In time‐course
MBNMA, we can rank on any function of the time‐course
model, which can allow for an extremely flexible
decision‐making framework. This could include ranking
based on any one of multiple time‐course parameters or
ranking on the predicted response at a desired follow‐up
time. For time‐course functions with multiple parame-
ters, note that the ranking of treatment effects may differ
for different time‐course parameters. For example, we
could have a treatment that ranks highest for ET50 indi-
cating that it acts more quickly than other treatments
but ranks lowest for Emax indicating that the overall
response is lower than for other treatments.
For models with less easily interpretable time‐course
parameters, it may also be beneficial to have an overall
ranking that takes into account the full time‐course rela-
tionship. Calculating the Area Under the Curve (AUC)
for the time‐course relationship for each treatment using
parameters estimated from the model is a pragmatic way
of doing this. However, care must be taken when choos-
ing the duration of time‐course over which to calculate
AUC, as treatment rankings may be sensitive to this
choice.
2.8 | Measures of model fit
Models are implemented using a Bayesian approach, and
therefore we use the posterior mean of the deviance
to compare the goodness‐of‐fit of the models,39 where
smaller values of deviance are preferred. Model selection
is based on the Deviance Information Criterion (DIC)
which represents a compromise between model fit and
model complexity,39,40 defined as the sum of the posterior
mean deviance (a measure of fit) and the effective num-
ber of parameters (a measure of complexity). We use pD
calculated using the Kullback‐Leibler information diver-
gence as the effective number of parameters.41 For the
selected final model (based on a univariate likelihood),
we also report the posterior mean of the residual deviance
(defined as the deviance for the model minus the devi-
ance for a saturated model), which can be compared with
the number of unconstrained data points to give an over-
all measure of model fit. Lack of fit is explored by plotting
an appropriate posterior summary (median if skewed) of
the contribution to the residual deviance for each data‐
point against time. Note, we do not compute residual
deviances for models with a multivariate likelihood in
which the correlation between time points is estimated
from the data, as the saturated model is not uniquely
defined.
2.9 | Model selection strategy
We propose a step‐by‐step approach for model selection
of time‐course relationships in MBNMA, recognising that
the available evidence may not be sufficient to be able to
estimate some of the more complex, but less restrictive,
models.
1. Plot study summaries (mean outcome) against time
to visually identify potential time‐course function
candidates and obtain expert opinion to assess their
biological plausibility if necessary.
2. Fit candidate time‐course models with fixed treat-
ment effects using a univariate likelihood that does
not account for correlations over time (univariate
models). Use simplifying modelling assumptions,
described above, if necessary to estimate the models
given the available data.
For each of these fitted models, plot the posterior
median of the contribution of each data‐point to the
residual deviance against time to check fit and to iden-
tify alternative time‐course relationships to explore.
Compare model fit statistics (posterior mean deviance
and DIC) and select a time‐course model with ade-
quate balance between fit and complexity (lowest
DIC) that also has biological plausibility.
3. For the selected univariate time‐course model, fit
random treatment effects models (if possible) with
the available data. Use model fit statistics and inspec-
tion of between studies SD parameters to assess pres-
ence of heterogeneity and choose between fixed and
random treatment effect models.
4. Check fit of the selected univariate model by compar-
ing posterior mean residual deviance to the total
number of data points
5. For the selected time‐course and treatment effects
model, fit models with multivariate likelihoods that
account for correlations over time with different
covariance structures. Select between the univariate
and multivariate formulations based on estimated
correlations and robustness of treatment effects
obtained (preferring the simpler models with lower
pV). Note the deviance statistics are not directly com-
parable for models with different likelihoods and so
cannot be used for model selection.
6. Check for consistency in final selected model (where
possible)
8 PEDDER ET AL.
a. Run UME model
b. If suggestive of possible inconsistency, perform
node splitting of closed loops
2.10 | Illustrative example—Pain in
osteoarthritis
The methodology is illustrated using a dataset of RCTs
investigating treatments for pain in patients with osteoar-
thritis. Pain was measured on the Western Ontario and
McMaster Universities Arthritis Index (WOMAC) scale42
and was recorded at multiple time points up to a maxi-
mum of 24 weeks. In order to maintain a consistent
imputation method for missing data across studies, only
those with last observation carried forward analyses
(LOCF) were included, as this was the imputation
method reported in the majority of papers. Agents with
multiple doses were split to form the network of treat-
ments, meaning that each combination of agent and dose
was considered to be a separate treatment. Although SDs
were typically available at baseline, they were missing for
269 out of 345 observations and were therefore imputed
accounting for changes over time using the method of
Boucher.43 We acknowledge that this is a high proportion
of data points for which to impute SD, but our aim here is
to illustrate the method rather than to provide clinically
useful treatment estimates. We note however that in
pharmacometrics, SD is not always reported as weighting
is often performed using sample size—in practice, we
would always recommend that SDs be reported and
measured.
The illustrative dataset consists of 23 RCTs comparing
29 treatments. Each study has a median of 3.5 (range: 2‐7)
follow‐up measurements, and all studies use LOCF
imputation for analyses. Figure 1 shows the network of
comparisons in the data, and Figure 2 shows mean
WOMAC pain in each study arm plotted over time for
each treatment. The dataset is freely available in the
Supporting Information (OsteoarthritisData.csv).44
2.11 | Implementation
Models were estimated using JAGS 4.2.0 (codes in the
Supporting Information). All fixed treatment effect
models were run on three independent chains for
20 000 iterations following 80 000 burn‐in iterations with
a thinning parameter of 10. For random treatment effect
models, convergence took more iterations—models were
run for 500 000 iterations following 400 000 burn‐in iter-
ations with a thinning parameter of 15. Gelman's r statis-
tic45 and visual inspection of the chains were used to
assess convergence. Vague normal prior distributions
(N(0,1000)) were given to the basic parameters d1,k, nui-
sance parameters μi, and treatment effect‐independent
time‐course parameters. For ET50 parameters in Emax
models, it was necessary to ensure that they only took
positive values so priors for these were specified on the
log‐scale. The between‐study SD and SDs on exchange-
able parameters were given uniform prior distributions
(U(0,5)). We inspect the posterior for the SDs to ensure
they are not being constrained by the prior. We also
assessed sensitivity of results to the prior by fitting the
same models using half‐normal prior distributions
(N(0,6.25)). In models with a multivariate likelihood, ρ
was given a uniform prior distribution (U(0,1)) to reflect
the belief that outcomes at different time points in the
same study are likely to be positively correlated. For
bivariate models with two nonintercept parameters, the
correlation between these parameters, ρδ, was given a
uniform prior distribution (U(−1,1)). For piecewise
time‐course models, knot location was selected through
trial‐and‐error by fitting models with different knot
values (allowing a minimum of 0.1 weeks between knots
in different models) and selecting the value from the best
fitting (lowest mean posterior deviance) model.
FIGURE 1 Network of treatment comparisons within the
MBNMA for the illustrative dataset of 24 RCTs for pain in
osteoarthritis. Each treatment is represented by a node. Where
direct RCT evidence exists for a particular comparison, the nodes
are connected by a line, the thickness of which is proportional to
the number of comparisons. All numbers represent doses (total
daily dose in mg). Abbreviations: Cel = Celebrex, Dul = Duloxetine,
Eto = Etoricoxib, Lum = Lumiracoxib, Naprox = Naproxcinod,
Nap = Naproxen, Oxy = Oxycodone, Rof = Rofecoxib,
Tram = Tramadol, Vald = Valdecoxib, NR = Dose not reported
[Colour figure can be viewed at wileyonlinelibrary.com]
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3 | RESULTS
Step 1. Visually inspect the data plotted against
time and consider biological plausibility of
time‐course functions
For all treatments, including placebo, visual inspection
of the data shows that WOMAC scores decrease over
time in a nonlinear fashion, with a rapid decline in pain
during the first 1 to 2 weeks that quickly levels out
(Figure 2). This suggests that a simple linear model will
not be a good fit for the data, but that exponential,
piecewise linear, or Emax models may be more suitable.
Both exponential and Emax models have good biological
plausibility and are frequently used for modelling phar-
macodynamic properties of drugs. However, the limited
number of observations at earlier follow‐up times sug-
gests that there may not be enough information to iden-
tify parameters that model the rapid decline, such as
ET50 parameters or parameters in the first piece of
piecewise models.
For two treatments (Duloxetine 90 mg/d and
Lumiracoxib (NR—dose not reported)), there is only data
from studies with baseline measurement and a single
follow‐up time compared with placebo, which is insuffi-
cient information to be able to identify any nonlinear
candidate time‐course function. We assumed that these
treatments followed the same time‐course function
(though with different time‐course parameter values) as
the other treatments in the network, and we consider
the impact of this assumption in the discussion.
Step 2. Compare time‐course models with univari-
ate likelihood and fixed treatment effects
Table 1 shows model fit statistics for linear, exponential,
piecewise linear, and Emax models (with various simplify-
ing assumptions). As expected, a linear time‐course
model gave a very poor fit to the data (Equation 3,
Figure 3, posterior mean deviance = 6935.2—Table 1).
An exponential time‐course was also a poor fit (Equation
2, Figure 3, posterior mean deviance = 5856.3—Table 1),
as it did not capture the fast rate of decline in WOMAC
scores that occurred within the first 2 weeks. A piecewise
linear time‐course with a knot at week one showed sub-
stantially better model fit (Equation 5, Figure 3, posterior
mean deviance = −189.3—Table 1) than the linear or
exponential models. However, by far, the best fitting
time‐course appeared to be an Emax model (Equation 4,
posterior mean deviances less than −441—Table 1).
Figure 3 shows that whilst the posterior mean contribu-
tion to the deviance displays a pattern for the linear and
exponential models (suggesting the time‐course is not
adequately captured), there is no systematic pattern dis-
cernible for the piecewise linear models and best‐fitting
Emax model (see below), and the deviance contributions
are much lower for the Emax model than the piecewise
linear model.
It was not possible to fit an Emax model with separate
treatment effects on the ET50 parameter, due to the lim-
ited number of observations at earlier time points in the
dataset. We were therefore obliged to make some simpli-
fying assumptions for ET50. We fitted class‐effect models
FIGURE 2 Plots of the mean WOMAC pain score for each of the studies in the pain in osteoarthritis dataset showing the most commonly
reported dose for each agent, plotted over time
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with exchangeable ET50 treatment effects (Equation 10)
with agent‐specific means (Emax model 1) or with a
common mean for all treatments (Emax model 3). We
also fitted class‐effect models with fixed ET50 treatment
effects (Equation 11) equal to agent‐specific values (Emax
model 2) or with an equal value for all treatments (Emax
model 4). For all of Emax models 1 to 4, we were also
obliged to further assume an exchangeable model for the
reference treatment effect (placebo in all studies), μET50;i
(Equation 12), to allow estimation.
Model fit was similar for Emax models 1 to 4, but the
model that assumed an equal treatment effect for ET50
for all treatments compared with placebo, common across
studies (Emax model 4), had the lowest DIC.
Step 3. Compare random and fixed treatment
effect models for selected time‐course model
Table 1 shows model fit statistics for a model that is iden-
tical to Emax model 4, but with a random treatment effects
model for Emax parameters (Equation 6) (Emax model 5).
The between‐study SD for treatment effects on Emax was
very low (0.09; 95%CrI: 0.00, 0.23), and although model
fit was slightly improved compared with the fixed effects
TABLE 1 Model fit statistics for time‐course models with univariate likelihood, fitted to the osteoarthritis pain dataset. For exchangeable
models, the heterogeneity parameter is reported as standard deviation (SD) = posterior mean SD (95% credible interval)
Model for λ1,i,k (Linear Slope,
Exponential Decay, or Emax) Model for λ2,i,k (Linear Slope, or ET50)
Time‐course model
Arm 1 effect,
μ1,i
Relative
treatment
effects, δ1,i,k
Arm 1 effect,
μ2,i
Relative treatment
effects, δ2,i,k DIC
a
Posterior
mean
devianceb pDc
Linear (λ1,i,k= slope) Unconstrained Fixed effect 7009.1 6935.2 73.9
Exponential
(λ1,i,k= decay rate)
Unconstrained Fixed effect 5931.8 5856.3 75.5
Piecewise linear
(λ1,i,k= slope period 1,
λ2,i,k= slope period 2,
knot = 0.1 wks)
Unconstrained Fixed effect Unconstrained Fixed effect −69.1 −189.3 120.2
Emax model 1
(λ1,i,k= Emax,
λ2,i,k= ET50)
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.53
(0.25, 1.10)
Fixed effect d2,1,k has an
exchangeable class effect
with an agent‐specific
mean, SD = 0.11 (0.01,
0.48)
−274.5 −441.2 166.7
Emax model 2
(λ1,i,k= Emax,
λ2,i,k= ET50)
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.50
(0.24, 0.97)
Fixed effect d2,1,khas a fixed
class effect for treatments
of same agent
−281.8 −443.1 161.3
Emax model 3
(λ1,i,k= Emax,
λ2,i,k= ET50)
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.61
(0.34, 1.10)
Fixed effect d2,1,k has an
exchangeable class effect
with common mean
across all treatments,
SD = 0.13 (0.01, 0.48)
−284.3 −444.0 159.6
Emax model 4
(λ1,i,k= Emax,
λ2,i,k= ET50)
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.64
(0.39, 1.15)
Fixed effect d2,1,k has a fixed
class effect constrained to
be equal for all
treatments
−289.9 −441.9 152.0
Emax model 5
(λ1,i,k= Emax,
λ2,i,k= ET50)
Unconstrained Random effects
(Equation 10),
SD = 0.09 (0.00,
0.23)
Exchangeable
(Equation 12),
SD = 0.65
(0.39, 1.16)
Fixed effect d2,1,k has a fixed
class effect constrained to
be equal for all
treatments
−287.9 −448.8 160.8
aDIC (= deviance + pD): It is a measure of model fit that penalises complexity.
bDeviance (= −2(log‐likelihood)): A measure of how closely the fitted values of the model fit the observed data.
cpD: The total number of effective parameters in the model, calculated using the Kullback‐Leibler information divergence.41
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model (Emax model 4), the added complexity resulted in a
higher DIC. There was insufficient data to be able to esti-
mate a bivariate random treatment effects model for Emax
and ET50 parameters (Equation 9). Nonetheless, we pro-
vide the JAGS code for this model in the Supporting
Information. Based on these results, we select the fixed
effects Emax model 4.
Step 4. Assess overall fit of selected univariate
model
The posterior mean residual deviance for Emax model 4
was 288.1, which is lower than the number of data points
(341), indicating a good fit to the data.
Step 5. Fit the selected time‐course model using a
multivariate likelihood
Accounting for residual correlation between time points
using a multivariate likelihood (Equation 1) for Emax
model 4 gave an estimated correlation of ρ = 0.28
(95%CrI 0.10, 0.41) when using a multivariate compound
symmetry covariance structure, and ρ = 0.50 (95%CrI
0.19, 0.65) when using a multivariate AR(1) covariance
structure (Table 2). Figure S1 (Supporting Information)
compares the univariate Emax model 4 treatment effects
with those from the equivalent multivariate specifications
with compound symmetry and autoregressive AR(1)
covariance structures. Estimates and their 95% CrIs
appear to be reasonably consistent between these models,
indicating that accounting for correlation leads to only
marginal differences in treatment estimates. Although
the differences are very slight, it is interesting to note that
use of a multivariate likelihood with compound symmetry
covariance structure typically leads to increased precision
of treatment estimates compared with the univariate like-
lihood model, whilst use of a multivariate likelihood with
AR(1) covariance structure has more of an effect on the
point estimate.
Predictions from the selected model (Emax model 4)
Figure 446 shows the predicted values from Emax model 4
for four illustrative treatments (others are given in Figure
S2 ‐ Supporting Information). There are many observa-
tions for treatments such as Celebrex 200 mg/d and
Naproxen 1000 mg/d, providing rich information on the
time‐course parameters, whilst for Duloxetine 90 mg/d
and Lumiracoxib (NR—dose not reported), the time‐
course is largely extrapolated and interpolated
AUC for time‐course relationships (Emax model 4)
Table 3 shows the median rank and their 95%CrI from
Emax model 4 for Emax treatment effects for each treat-
ment, and the AUC for each treatment calculated over
24 weeks follow‐up (the maximum latest follow‐up in
any of the included studies). As ET50 was constrained to
be equal across all treatments, the rankings are only
dependent on Emax, and therefore Emax rankings match
the AUC rankings. Etoricoxib 60 mg/d was the highest
median ranked treatment for both AUC and Emax.
Step 6. Test for inconsistency
In the osteoarthritis dataset, all studies included a
placebo arm. Within the contrast‐based NMA approach,
the relative effects within a study are only estimated for
each treatment versus the study reference treatment—it
FIGURE 3 Median posterior residual
deviance contributions over time from
univariate fixed treatment effects models
with linear, exponential, piecewise linear,
and Emax (model 4) time‐course
relationships in the pain in osteoarthritis
dataset. Residual deviances closer to 0
indicate a better fitting model.
Nonlinearity in these plots indicates that
the effect of time has not been properly
accounted for. The scales for residual
deviance vary between the upper and
lower panels
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is not necessary to estimate relative effects between
nonreference treatments within a multi‐arm study
because these will be defined by the difference between
the relative effects for each treatment versus the study
reference, as each study must be internally consistent.
Therefore, there were no closed loops of treatments in
the network that were made up of independent sources
of evidence, and as a result it was not possible to test
for inconsistency (Figure S3A ‐ Supporting Information).
For illustrative purposes, to create a dataset in which it
is possible to test for inconsistency, we expanded our
inclusion criteria to all studies irrespective of their
FIGURE 4 Predicted means and 95% CrI from the final model (Emax model 4) for the pain in osteoarthritis dataset for Celebrex 200 mg/d,
Duloxetine 90 mg/d, Lumiracoxib (dose not reported), and Naproxen 1000 mg/d, plotted over time. The thicker red line indicates the
assumed placebo response (calculated from the data). The shading of the 95% CrI indicates observations present in the dataset at each time
point [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Model fit statistics for the Emax model 4 time‐course model (see Table 1), comparing univariate and multivariate likelihoods,
fitted to the osteoarthritis pain dataset. For the exchangeable baseline parameters, standard deviations (SD) are reported as posterior mean SD
(95% credible interval). Correlation is reported as posterior mean (95% credible interval)
Model for λ1,i,k (Emax) Model for λ2,i,k (ET50)
Time‐course model
Arm 1 effect,
μ1,i
Relative
treatment
effects, δ1,i,k
Arm 1 effect,
μ2,i
Relative
treatment
effects, δ2,i,k
Correlation,
ρ DICa
Posterior
mean
devianceb pDc
Emax model 4
univariate likelihood
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.64
(0.39, 1.15)
Fixed effect, d2,1,k
equal for all
treatments
0 −289.9 −441.9 152.0
Emax model 4
multivariate
likelihood, compound
symmetry
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.68
(0.43, 1.18)
Fixed effect, d2,1,k
equal for all
treatments
0.28 (0.10,
0.41)
−266.2 −425.8 159.6
Emax model 4
multivariate
likelihood, AR(1)
Unconstrained Fixed effect Exchangeable
(Equation 12),
SD = 0.66
(0.41, 1.17)
Fixed effect, d2,1,k
equal for all
treatments
0.50 (0.19,
0.65)
−278.9 −437.0 158.1
aDIC (= deviance + pD): It is a measure of model fit that penalises complexity.
bDeviance (= −2(log‐likelihood)): A measure of how closely the fitted values of the model fit the observed data.
cpD: The total number of effective parameters in the model, calculated using the Kullback‐Leibler information divergence.41
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method of imputation. This added an extra seven studies
to create an “augmented dataset” (30 studies in total).
The augmented dataset is freely available in the
Supporting Information (AugmentedInconsistencyData.
csv).44 One of these additional studies47 compared
Celebrex 200 mg/d, Rofecoxib 25 mg/d, and Naproxen
100 mg/d but not Placebo. This created two loops in the
network in which direct and indirect estimates came
from independent sources, meaning it was possible to test
for inconsistency (Figure S3B ‐ Supporting Information).
In the augmented dataset, results from the UME
model were very similar to the MBNMA model (Emax
model 4). Posterior mean residual deviance was 374.0
for the UME model compared with −370.3 for the
MBNMA model, whilst the between‐study SD for the ref-
erence treatment effect for ET50 was almost identical for
both UME (0.69 (95%CrI: 0.43, 1.18) and MBNMA models
(0.69 (95%CrI: −0.44, 1.18). There is therefore no evi-
dence to invalidate the consistency assumption.
A node splitting model was fitted for the two closed
loops of treatments in the network that comprised inde-
pendent data sources, giving two comparisons on which
to node split (Figure S3B ‐ Supporting Information).
For both comparisons, the MBNMA estimate was
effectively a weighted average of the direct and indirect
estimates, as would be expected, though in both the indi-
rect evidence is more precise and therefore has the
greatest influence on the MBNMA result (Figure 5). The
TABLE 3 Median (95%CrI) rankings (1 = best) for AUC and Emax treatment effects for Emax model 4. Simplifying assumptions on ET50
that constrain it to be equal across all treatments mean that the rankings for AUC are identical to the rankings for Emax treatment effects
Treatment Median AUC Rank (95% CrI) Median Emax Rank (95% CrI)
Etoricoxib 60 mg/d 1 (1, 3) 1 (1, 3)
Etoricoxib 90 mg/d 2 (1, 4) 2 (1, 4)
Rofecoxib 125 mg/d 3 (1, 6) 3 (1, 6)
Etoricoxib 30 mg/d 4 (3, 12) 4 (3, 12)
Oxycodone 44 mg/d 5 (1, 25) 5 (1, 25)
Rofecoxib 25 mg/d 6 (4, 15) 6 (4, 15)
Naproxcinod 1500 mg/d 7 (5, 11) 7 (5, 11)
Naproxen 1000 mg/d 10 (6, 14) 10 (6, 14)
Celebrex 400 mg/d 11 (6, 21) 11 (6, 21)
Etoricoxib 10 mg/d 12 (5, 27) 12 (5, 27)
Naproxcinod 750 mg/d 13 (7, 23) 13 (7, 23)
Etoricoxib 5 mg/d 14 (5, 28) 14 (5, 28)
Lumiracoxib ( not reported) 14 (7, 24) 14 (7, 24)
Valdecoxib 20 mg/d 15 (6, 25) 15 (6, 25)
Rofecoxib 12 mg/d 16 (7, 25) 16 (7, 25)
Lumiracoxib 100 mg/d 17 (11, 23) 17 (11, 23)
Lumiracoxib 400 mg/d 17 (10, 24) 17 (10, 24)
Tramadol 300 mg/d 17 (8, 24) 17 (8, 24)
Valdecoxib 10 mg/d 17 (7, 26) 17 (7, 26)
Celebrex 200 mg/d 18 (13, 23) 18 (13, 23)
Lumiracoxib 200 mg/d 19 (12, 24) 19 (12, 24)
Valdecoxib 5 mg/d 19 (8, 26) 19 (8, 26)
Tramadol 400 mg/d 20 (8, 27) 20 (8, 27)
Duloxetine 90 mg/d 22 (8, 28) 22 (8, 28)
Celebrex 100 mg/d 25 (17, 27) 25 (17, 27)
Tramadol 200 mg/d 25 (17, 27) 25 (17, 27)
Tramadol 100 mg/d 27 (22, 28) 27 (22, 28)
Placebo 0 mg/d 28 (27, 29) 28 (27, 29)
Naproxcinod 250 mg/d 29 (26, 29) 29 (26, 29)
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Bayesian P‐value representing the overlap of the posterior
distributions for the direct and indirect evidence was 0.69
for Celebrex 200 mg/d vs Naproxen 1000 mg/d and 0.79
for Celebrex 200 mg/d vs Rofecoxib 25 mg/d indicating
no evidence of inconsistency in either loop of treatments.
3.2 | Model checking
For all models for which results are reported, Gelman's r
statistic and visual inspection of the chains were indica-
tive of convergence. Convergence diagnostic plots for
the final model (Emax model 4) and for a nonconverging
“ideal” Emax model with no simplifying assumptions on
ET50 are given in the Supporting Information.
Posterior densities were not constrained or strongly
influenced by priors. In the final model (Emax model 4),
the SD for the exchangeable study reference treatment
effect was 0.64 (95%CrI: 0.39, 1.15) when using a uniform
(U(0,5)) prior and 0.64 (95%CrI: 0.39, 1.16) when using a
half‐normal () prior (Figure S4 ‐ Supporting Information).
For the random Emax treatment effects model (Emax model
5), the between‐study SD for random Emax treatment
effects was 0.09 (95%CrI: 0.00, 0.23) when using either a
uniform (U(0,5)) prior or a half‐normal () prior, suggesting
the choice of prior is not influential.
4 | DISCUSSION
We have presented a method to pool evidence from trials
that form a network of comparisons across multiple
treatments, reporting continuous summary outcome
measures over multiple time points. The method respects
the randomisation in RCTs, can include a variety of dif-
ferent functional forms for the time‐course, allows for
testing of consistency of the evidence, and demonstrates
how a multivariate likelihood can be used to account
for residual correlation between time points.
In the pain in osteoarthritis dataset, we found that the
Emax model provided the best fit and allowed for the
greatest degree of flexibility, both in the time‐course
shape and in the specification of various time‐course
parameters (Emax and ET50). The Emax model with the
lowest DIC (Emax model 4) assumed a fixed effect across
all nonplacebo treatments on ET50 (Equation 12). In this
model, we estimated AUC of the time‐course function
over 24 weeks follow‐up and found Etoricoxib 60 mg/d
to have the highest ranked AUC.
Whilst WOMAC pain in this dataset was measured as
a continuous outcome, MBNMA can also be performed
on any data provided it can be summarised as a continu-
ous outcome that can be assumed to have a normal like-
lihood. This therefore allows for binary data (ie, %
respondents at each follow‐up time) to be analysed using
MBNMA if they are summarised as log‐odds and are not
near the boundary probabilities (0% or 100%).
4.1 | Time‐course function
Previous methods for performing NMA on longitudinal
data have typically accounted for the dependency
between different follow‐up times by either modelling
an appropriate time‐course function18,19 or using non-
parametric approaches to account for responses at each
time point.21,34 To our knowledge, none of the methods
FIGURE 5 Posterior densities for the effect of naproxen (1000 mg/d) versus Celebrex (200 mg/d) and Rofecoxib (25 mg/d) versus Celebrex
(200 mg/d) on Emax for the direct and indirect evidence arising from node splitting when testing for inconsistency using Emax model 4 for
the augmented dataset. Bayesian P‐value of 0.69 and 0.79, respectively, representing the proportion of the densities that overlap
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for modelling longitudinal continuous data in NMA have
described methods for testing inconsistency.
Jansen et al19 used fractional polynomials to model a
nonlinear trend, with an inflated variance for each time
point to approximate correlations between observations.
These allow for a very flexible shape for modelling the
time‐course relationship. However, fractional polyno-
mials are difficult to interpret and may not have a clear
biological justification, making them less desirable for
use in pharmacometric studies, where the objective is to
define how the efficacy of a treatment changes over
time rather than to simply account for it. For modelling
time‐course in pharmacometrics, exponential and Emax
functions are typically used, as these have a biological
basis in describing the mechanism of drug action and
elimination from the body.48 Taking this into account,
Ding and Fu18 modelled an exponential shape in NMA
and described how their model could be adapted for a sig-
moid shape similar to that of an Emax function.
Nonparametric models that do not specify a particular
time‐course relationship have also been proposed,
although these do not allow for any interpolation or
extrapolation of treatment effects at unmeasured points
in time, which makes them less applicable to drug devel-
opment. Ishak et al21 used a multivariate likelihood to
account for the dependency between different time
points. Dakin et al34 used a saturated model to estimate
treatment effects separately for different time bins,
although for this method more data are required to reli-
ably estimate the treatment effects for each bin.
One of the strengths of our MBNMA framework is
that information on time‐course characteristics can be
inferred from other treatments or agents by assuming
varying degrees of similarity and thus improving
identifiability. However, sharing information on time‐
course parameters across a network assumes exchange-
ability, and it is important to be aware of the implications
of this assumption and to consider whether it holds
across different agents or classes of treatments.
4.2 | Correlation between time points
Having selected an appropriate time‐course relationship
in the pain in osteoarthritis dataset, we found that esti-
mated residual correlation was reasonably high. This was
in contrast to our expectation that explicitly modelling
the time‐course should have generated conditional inde-
pendence. However, accounting for this correlation had
only a slight impact on treatment effect estimates or 95%
CrIs. This suggests that for MBNMA where the focus is
on summary estimates, whilst accurately characterising
the within‐study correlation and covariance structure
may be important, it is likely to be less critical than accu-
rately characterising the time‐course. With regards to the
importance of modelling within‐study correlation, there
is some debate in the literature. A simulation study by
Ishak et al49 suggests that the impact of ignoring within‐
study correlation on treatment estimates may typically be
small, even in cases where there has been no specific
modelling of a time‐course function. However, Riley50
has shown that this is only the case when between‐study
variation is large relative to within‐study variation, or
when there are complete data with only small differences
in the within‐study covariance matrices across studies.
Ahn and French2 support this position, demonstrating
that ignoring correlation in longitudinal MBMA led to
inflated residual variance. We are currently performing a
simulation study to further examine the relationship
between time‐course fit and correlation in MBNMA.
Note that the estimated covariance matrix in the mul-
tivariate likelihood will depend on the time‐course model
fitted, and the strength and importance of correlations
between time points are also likely to depend consider-
ably on how close together follow‐up measurements are
in time, with closer measurements expected to be more
strongly correlated.
Previous longitudinal MBMA methods that account
for correlated residuals have been developed in a
frequentist framework, using NONMEM software to
allow for modelling of interarm variability in addition to
interstudy variability.2 The authors used an exponential
model for the time‐course and also accounted for nonlin-
ear dose‐response in their model. Although we follow a
Bayesian approach and our model is formulated some-
what differently, our multivariate model with a com-
pound symmetry covariance structure is similar to their
method. However, the key difference is that our approach
respects randomisation and allows for inconsistency test-
ing. Without these features, the methods are unlikely to
meet the requirements of reimbursement agencies.
4.3 | Modelling assumptions
For our selected Emax model in the pain in osteoarthritis
dataset (Emax model 4), assuming a fixed effect across all
nonplacebo treatments for ET50, whilst allowing all treat-
ment effects to be different for Emax implies that the onset
of action is the same for the different treatments relative
to placebo, but that treatments differ in the maximal
change in outcome achieved. In practice, this might be
considered an unusual modelling assumption, as one
might expect ET50 to differ between active treatments,
particularly for those acting via different biological path-
ways. However, the onset for all these treatments was
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very rapid, and there were insufficient observations at
early time points to reliably estimate this. In fact, none
of the included studies report WOMAC scores within a
week from baseline. Given that this is later than the esti-
mated ET50 (approximately 0.6 weeks), it is not surprising
that this parameter is difficult to estimate. For this exam-
ple, we would therefore caution against making infer-
ences at very early time points. Using informative prior
distributions for the τ2ET50 or for dET50;1;k parameters for
which information is sparse may improve estimation.
Information from noncomparative pharmacodynamic
studies of different agents may be useful to provide sup-
port for specific prior distributions. Another approach
may be to incorporate information from other treatments
in a more biologically plausible manner, such as by using
the dose‐response relationships between treatments
within an agent.17
Explicitly modelling the bivariate correlation between
Emax and ET50 may in some circumstances also provide
additional information to help identify ET50 and reduce
the need for such strong simplifying assumptions. This
is likely to be the case when correlation between Emax
and ET50 is high. However, in the pain in osteoarthritis
example, this still was not sufficient to help identify
ET50, even when alternative parameterizations for the
covariance matrix were used.31
Within time‐course MBNMA, it is necessary to assume
the same time‐course function for the included set of treat-
ments. Whilst themean responses over time for most treat-
ments supported the use of an Emax function, there were
only two observations (baseline and one follow‐up mea-
surement) for studies comparing Lumiracoxib (NR—dose
not reported) vs Placebo and Duloxetine 90 mg/d vs
Placebo.
For Lumiracoxib NR, it was reasonable to assume that
the time‐course function will be similar to other doses
of Lumiracoxib for which there are more observations.
However, there are no other doses of Duloxetine to make
an equivalent assumption, and as the mechanism of
Duloxetine is also different to any other agent in the
dataset, it may follow a different time‐course function.
Yet, as this treatment did not contribute any indirect evi-
dence to the rest of the network (which could induce bias
in other treatment estimates if modelled appropriately)
and there was no evidence to suggest a different time‐
course function would be applicable for this treatment,
we feel it is reasonable to assume a similar time‐course
function to other treatments provided treatment effect
estimates for Duloxetine 90 mg/d are interpreted
with caution. This case highlights the importance of
understanding the underlying pharmacometrics of treat-
ments in the data, and of dialogue between clinicians,
pharmacometricians, and analysts.
An additional assumption made in all the Emax models
due to the inclusion of Lumiracoxib NR and Duloxetine
90 mg/d was that of an exchangeable placebo (Equation
12), as the lack of multiple follow‐up measurements
made separate estimation of all three parameters for the
time‐course (E0, ET50, and Emax) impossible for these
comparisons. This is likely to have caused a certain
degree of shrinkage and may therefore induce bias in
treatment estimates for ET50 due to back‐propagation of
the information on the reference treatment.9
4.4 | Inconsistency
In NMA, two approaches are typically used for dealing
with longitudinal studies. A single consistent time point
may be used for analysis across studies, ignoring evidence
from other time points. Alternatively, the final time point
from studies with different follow‐up times may be
“lumped” together to allow for networks to be connected,
yet this lumping can often be a source of inconsistency
and/or heterogeneity.16 Whilst MBNMA solves the issue
of lumping together studies with different follow‐up times
or discarding information on multiple time points, the
choice of model will affect the presence of inconsistency.
We suspect that a poorly fitting time‐course model may
induce inconsistency. It is therefore important to explore
different functional forms and identify a good model
before testing for inconsistency.
For the purposes of drug development, the potential
for inconsistency testing in MBNMA may in fact be rela-
tively rare. The typical design of Phase II trials is multi‐
arm placebo‐controlled, meaning that there are no closed
loops of treatments that are not made up of multi‐arm
trials (as in the illustrative osteoarthritis dataset). As
these trials must inherently be internally consistent, this
provides no means to test for inconsistency. However,
we are still relying on the consistency assumptions to
make indirect comparisons, so although in these cases
we cannot formally test for inconsistency it is important
to consider whether these assumptions are valid.
For the pain in osteoarthritis augmented dataset, we did
not find any evidence of inconsistency in the augmented
dataset when including non‐LOCF studies, and parameter
estimates were robust to their inclusion. In practice, we
would recommend careful consideration of inclusion
criteria to ensure only studies on which the consistency
assumption is expected to hold are included.13
It is worth noting that a standard NMA performed by
“lumping” the latest time point in each of the studies
(an approach frequently used but not one that we would
recommend) highlights the benefit of performing
MBNMA when dealing with different follow‐up times. In
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terms of DIC, a random treatment effects NMA was pre-
ferred over a fixed treatment effects NMA, with a nonzero
between‐study SD (0.25 (95%CrI: 0.17, 0.36)). A Bayesian
P‐value for the node‐split of Celebrex 200 mg/d vs
Naproxen 1000 mg/d was 0.011 and for Celebrex 200 mg/
d vs Rofecoxib 25 mg/d was 0.100 suggesting reasonable
evidence of inconsistency in both comparisons that was
particularly concerning given that the direct and indirect
evidence for both showed opposite directions of effect.
Therefore, by accounting for time‐course using MBNMA,
we have explained heterogeneity and inconsistency that
can arise when using standard NMA methodology.
4.5 | Limitations
There are a few limitations to the methodology that we
seek to investigate further in simulation studies. The first
is that the quantity of data required for MBNMA may be
significant, particularly for more complex time‐course
functions. This therefore means that analyses may typi-
cally require strong simplifying assumptions within the
modelling that are difficult to test. This could relate to
the assumption that time‐course functions are the same
across all treatments within the network, but also to the
need to interpolate or extrapolate over the time‐course
when few observations are available for a particular
treatment.
We also do not fully understand the importance of cor-
rectly accounting for the correlation between time points,
and how failure to do this might affect estimates for
different parameters in the model. We believe that the
impact of this is likely to depend on the key parameters
of interest in the model. Simulation can help to shed light
on this issue.
4.6 | Future direction
In future work, we plan to incorporate simultaneous dose‐
response and time‐course modelling into the MBNMA
framework,17 and to develop simulation studies to explore
the robustness and data requirements of dose‐response,
time‐course, and methods for assessing inconsistency
in MBNMA. We are also developing an R package for
MBNMA to facilitate its implementation.
5 | CONCLUSION
MBNMA combines the strengths of both MBMA and
NMA, leading to a statistically robust framework for syn-
thesising evidence on multiple treatments at multiple
time points whilst preserving randomisation and allowing
for assessment of consistency. By unifying these statistical
techniques, the methods can provide both the informa-
tion needed to inform drug‐development decisions, and
also the rigour required by reimbursement agencies to
incorporate valuable evidence from drug development
into the decision‐making process.
5.1 | Highlights
Within drug development, MBMA is increasingly used to
inform drug decisions such as whether to proceed to fur-
ther clinical trials, and if so, what the design of the study
should be. However, these types of analyses typically
model each drug separately by pooling individual study
arms, which breaks the randomisation and ignores
within‐study comparisons, effectively losing the advan-
tages of the RCT design and potentially inducing bias in
the resulting estimates.
Our MBNMA framework preserves randomisation by
modelling relative effects and allows for testing of incon-
sistency between direct and indirect evidence. This man-
uscript extends previous methodology on dose‐response
MBNMA to allow the modelling of nonlinear time‐course
characteristics, incorporating multiple study time points
and accounting for correlation between them.
MBNMA combines techniques from two different
disciplines, pharmacometrics and evidence synthesis,
thereby acting as a bridge between early phase clinical
research and Health Technology Appraisal.
Glossary
Agent = an intervention/compound/drug
Identifiability = the capacity for parameters in a model to
be reliably estimated
Treatment = a specific dose and agent combination.
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